About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 4NCT05606471

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

The very-low calorie diet (VLCD) is a highly effective and safe way to rapidly lose significant amounts of weight and dramatically improve blood sugar control in a short period of time (typically 8-12...

Lead sponsor: University of Nottingham•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Nottingham

Collaborators

Medical Research Council

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Confirmed Type 2 Diabetes Mellitus
•Body mass index \> 27kg·m-2
•Eligible for VLCD, Semaglutide (or both), within routine practice
•Ability to provide informed consent

Exclusion Criteria

•BMI \> 50kg·m-2
•Current pregnancy or breastfeeding, or intention to fall pregnant within the next 3 months
•Uncontrolled hypertension (blood pressure \>200/120mmHg)
•Current treatment with insulin
•Current or recent use of GLP-1 agonists
•Previous adverse reaction to a GLP-1 agonist
•Current or recent involvement in a VLCD programme (within the last 12 months)
•History of \>5% weight loss within the preceding 12 months
•Ingestion of exogenous D2O within the preceding 12 months
•Background of clinically significant cardiovascular, cerebrovascular or respiratory disease, neurological disorders or musculoskeletal problems
•History of malignancy undergoing current treatment or palliation
•History of any medical condition contraindicating the use of GLP-1 agonist medication
•Any other medical condition deemed by the investigators to preclude inclusion into the study

Related studies

Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)

NCT05277558 · Type2 Diabetes, Type 2 Diabetes Mellitus in Obese, and more

COMPLETEDPhase 2

Phentermine/Topiramate for Uric Acid Stones

NCT04621929 · Obesity, Uric Acid Stones, and more

The Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic Adults

NCT04931836 · Obesity, Overweight, and more

Not Yet RecruitingNA

LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences

NCT06442150 · Type 2 Diabetes Mellitus in Obese, Type 2 Diabetes

TERMINATEDPhase 3

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074 · CKD, Diabetic Kidney Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 4, 2022Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment45

Start dateSep 2021

Last updatedNov 4, 2022

Condition

Type 2 Diabetes Mellitus in Obese

Locations shown

University of Nottingham, Royal Derby Hospital Centre

Derby

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2022Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions